📰 Breaking News: Lessons Learnt & Insights from DSTBTD Restructuring Plan

Notice of dividend

Immodulon Therapeutics Limited

administration Company no. 06223291 Published 09 September 2026

In short: Immodulon Therapeutics Limited (company no. 06223291) was the subject of a formal insolvency notice, according to a Notice of dividend notice published in The London Gazette on 09 September 2026. The office holder is Brian Milne, appointed 13 December 2024. The case is before the Business and Property Courts in England And Wales (case CR-2024-007586).

The administrator intends to declare a first and final dividend to unsecured creditors of Immodulon Therapeutics Limited and sets a last date for proving claims of 8 October 2026.

Notice details

Company
Immodulon Therapeutics Limited
Company number
06223291
Registered office
c/o Quantuma Advisory Limited, 7th Floor, 20 St Andrew Street, London, EC4A 3AG
Principal trading address
6-9 The Square, Stockley Park, Uxbridge, UB11 1FW
Court
High Court of Justice Business and Property Courts of England and Wales
Case number
CR-2024-007586
Administrator
Brian Milne
Administrator address
Third Floor, Turnberry House, 175 West George St, Glasgow, G2 2LB
Administrator IP number
9381
Date of appointment
13 December 2024
Appointed by
The directors of the Company
Contact name
Susan McArthur
Contact email
[email protected]
Contact telephone
0131 659 9965
Last date for proving
8 October 2026
Prescribed part value
£72,713.50

What this notice means

This is a formal notice published in The London Gazette relating to the company's insolvency, restructuring or closure.

Read more: What is Insolvency?.

All notices for Immodulon Therapeutics Limited

2 Gazette notices on record for company no. 06223291, newest first. The full history, with last filed accounts, is on the Immodulon Therapeutics Limited company record.

  1. Other corporate insolvency notices 09 Sep 2026

How does this notice affect you?

Choose what applies and we'll point you at the right next step.

Would rather just talk? 020 7720 8000

Is your own business showing the same warning signs?

Falling margins, stretched creditors, overdue filings and HMRC arrears usually appear months before a Gazette notice. Directors who act at that stage keep far more options open, from an informal turnaround to a CVA or restructuring plan.

Related guidance

Free, practical guides from K2 on what this kind of notice means for directors.

More other notices

← Back to all notices

Frequently asked questions

Has Immodulon Therapeutics Limited gone into liquidation?

The London Gazette published a Notice of dividend for Immodulon Therapeutics Limited (company no. 06223291) on 09 September 2026. This is a formal notice published in The London Gazette relating to the company's insolvency, restructuring or closure.

What does a Notice of dividend mean?

This is a formal notice published in The London Gazette relating to the company's insolvency, restructuring or closure.

Who is dealing with the liquidation?

The office holder named in the notice: Brian Milne, appointed 13 December 2024. Creditors, employees and anyone holding goods or money belonging to the company should contact them directly, quoting the company number and case number CR-2024-007586.

The company owes me money — what can I do?

You are a creditor in the process. The insolvency practitioner named in the notice will write to known creditors and invite claims; if you have not heard from them, contact them with your invoices. Unsecured creditors rank after fixed-charge holders, the costs of the insolvency, preferential creditors and floating-charge holders, so recovery depends on what is left in the estate.

I worked there — how do I claim what I am owed?

Unpaid wages, holiday pay and statutory redundancy are claimed from the government's Redundancy Payments Service, not from the company or from K2. The insolvency practitioner named in this notice should give you a case reference to claim with.

Source: The London Gazette and Companies House. Contains public sector information licensed under the Open Government Licence v3.0. © Crown copyright. This page is provided by K2 Partners for information only and is not legal or financial advice.